ClinicalTrials.gg
CompletedNCT07200596Updated Jun 11, 2026

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects

A Phase 1 interventional study of SHR-3045 Injection and SHR-3045 Placebo Injection in Rheumatoid Arthritis (RA), sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 11
16 · median 30
Started
2025
with 1 other
Phase 1
8 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 1, and was the 10th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with ability to understand the trial procedures and possible adverse events, voluntary participation in the trial.
  2. Subjects who can provide written .
  3. Males or females aged 18-55 years (both inclusive).
  4. Males with body weight ≥ 50 kg, or females with body weight ≥ 45 kg, (BMI) 19-28 kg/m2 (both inclusive).
  5. No abnormalities in the medical history, general physical examinations, vital signs and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  1. Participation in clinical trials of other drugs or medical devices within 3 months prior to screening.
  2. Known or suspected history of drug abuse.
  3. Addiction to tobacco and alcohol.
  4. Individuals who are unable to adhere to the dietary requirements of this trial during the study period.
  5. Judged by the investigator, there are any other conditions that interfere with the results evaluation of the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    SHR-3045 Group

    Drug: SHR-3045 Injection

  • Placebo comparator
    SHR-3045 Placebo Group

    Drug: SHR-3045 Placebo Injection

Interventions

  • SHR-3045 injection.

  • DrugSHR-3045 Placebo Injection

    SHR-3045 placebo injection.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: From screening period up to Day 113.

Secondary outcomes

  1. Area under the concentration-time curve from time 0 to the last time point after SHR-3045 administration (AUC0-last).

    Time frame: Post-dose at Day 1 to Day 113.

  2. Area under the concentration-time curve from time 0 to infinity after SHR-3045 administration (AUC0-inf).

    Time frame: Post-dose at Day 1 to Day 113.

  3. Maximum observed concentration of SHR-3045 (Cmax).

    Time frame: Post-dose at Day 1 to Day 113.

  4. Time to maximum observed concentration of SHR-3045 (Tmax).

    Time frame: Post-dose at Day 1 to Day 113.

  5. Apparent clearance of SHR-3045 (CL/F).

    Time frame: Post-dose at Day 1 to Day 113.

  6. Apparent volume of distribution of SHR-3045 (Vz/F).

    Time frame: Post-dose at Day 1 to Day 113.

  7. Terminal elimination half-life of SHR-3045 (t1/2).

    Time frame: Post-dose at Day 1 to Day 113.

07

Study locations

1 site
  • The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)
    Hefei, Anhui 230001, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 1, 2025
StartActual
Oct 8, 2025
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07200596
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Oct 8, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Jun 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-3045

Start the discussion